BioVie (BIVI) vs BioLineRx (BLRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioVie (BIVI) has outperformed BioLineRx (BLRX) over the past year, losing 35.0% versus a loss of 49.8%. Over five years, BLRX leads with a -98.2% price change compared with -99.8% for BIVI. BioVie is the larger company by market cap ($11.1 million vs $11.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIVI | BLRX |
|---|---|---|
| Share price | $1.28 | $2.21 |
| Market cap | $11.11M | $11.00M |
| 1-day change | -8.57% | +0.23% |
| YTD return | +10.34% | -20.22% |
| 1-year return | -35.03% | -49.77% |
| 5-year return | -99.78% | -98.19% |
| EPS (TTM) | $-3.05 | $0.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.79 | $4.50 |
| 52-week low | $0.82 | $2.15 |
| Distance from 52-week high | -66.23% | -50.89% |
| Analyst consensus | none | none |
| Avg. price target upside | +310.94% | +895.48% |
| Average volume | 4.60M | 16.27K |
| Shares outstanding | 8.68M | 4.98M |
| Employees | 13 | 20 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIVI has outperformed BLRX by 14.7 percentage points over the past year.
About BioVie
BIVI stock →BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Healthcare · Biotechnology · 13 employees
About BioLineRx
BLRX stock →BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Healthcare · Biotechnology · 20 employees
BIVI vs BLRX FAQ
Which is bigger, BioVie or BioLineRx?
BioVie (BIVI) is larger, with a market capitalization of $11.11M compared with $11.00M for BioLineRx (BLRX).
Which stock has performed better over the past year, BIVI or BLRX?
BIVI returned -35.03% over the past 12 months, compared with -49.77% for BLRX (price return, excluding dividends). Past performance does not predict future results.
Are BioVie and BioLineRx in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.